A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm that apricitabine does not induce any clinically
significant effect upon electrocardiogram (ECG) parameters at doses consistent with the
maximum exposure expected to occur in clinical practice.